The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management (Q36187070)

12 August 2017

1 reference

title

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management (English)

1 reference

12 August 2017

Octaviano A Roges

1

1 reference

12 August 2017

Marilyn Baron

series ordinal

2

1 reference

12 August 2017

Athena Philis-Tsimikas

series ordinal

3

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

14

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

705-727

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Exon duplication and divergence in the human preproglucagon gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

GLP-1 release in man after lower large bowel resection or intrarectal glucose administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Neural regulation of glucagon-like peptide-1 secretion in pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno--ileal loop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Further characterisation of the 'ileal brake' reflex in man--effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

A role for glucagon-like peptide-1 in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The major glucagon-like peptide-1 metabolite, GLP-1-(9-36)-amide, does not affect glucose or insulin levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

CD26 antigen is a surface dipeptidyl peptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The structure and function of CD26 in the T-cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Human colon produces fully processed glucagon-like peptide-1 (7-36) amide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.6.705

10.1517/13543784.14.6.705

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference